LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that pharmaceutical-grade Niagen Plusâ"¢ products, Niagen IV and injections, are now offered at more than 50 iCRYO locations across the U.S., bringing availability to more than 900 clinics nationwide. The partnership aligns Niagen Bioscience's innovative, science-backed, pharmaceutical-grade NAD ...

Financial Data and Key Metrics Changes - In Q4 2024, the company reported record revenues of $29.1 million, a 37% increase year-over-year, and net income of $7.2 million [8][23] - For the full year 2024, net revenues reached $99.6 million, reflecting a 19% growth year-over-year, with net income of $8.6 million, a significant turnaround from a net loss of $4.9 million in 2023 [8][22] - The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt [9][28] Business Line Data and Key Metrics Changes - E-commerce channel net sales were $17.3 million, a 30% increase year-over-year, while food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million, a 96% increase year-over-year [9][24] - Tru Niagen-related sales increased by 29%, driven by a 30% growth in e-commerce and a 26% increase in combined Watsons and other B2B sales [23][24] Market Data and Key Metrics Changes - The company noted a growing demand for NAD-boosting products, with an increase in companies entering the market, some of which engage in misleading practices [10][11] - The company is actively working to address fraudulent activities in the market and is advocating for more regulatory oversight [11][105] Company Strategy and Development Direction - The company plans to leverage its position as an industry leader to promote consumer safety and product excellence [12] - A name change is anticipated to better align with the company's evolving mission and strategic direction [16][33] - The company is focused on expanding its pharmaceutical-grade ingredient business and enhancing its e-commerce presence [30][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the company's strong financial discipline and operational efficiency [22][32] - The company expects approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships [30][32] - Management acknowledged potential risks related to supply chain issues but indicated confidence in resolving these challenges [62] Other Important Information - The company has initiated communication with the FDA regarding an investigational new drug application for NR in treating ataxia telangiectasia and is awaiting results from the NO-PARK study for Parkinson's disease [15][16] - The company plans to introduce new formulations and enhance existing products, including a subcutaneous injection version of Niagen [84] Q&A Session Summary Question: Can you discuss the stick packs and their performance? - The stick packs contain 300 milligrams and have seen increased sales, with plans for a marketing campaign in 2025 [36] Question: What is the status of the Elysium settlement? - The second payment of $1.3 million from the Elysium settlement is expected by the end of March [40] Question: When can we expect results from the NO-PARK study? - The study will be completed by June, but results may not be available until later [42] Question: How is the food-grade Niagen segment performing? - The food-grade ingredient business is expected to continue growing, with increased awareness and new partnerships [45] Question: What are the drivers behind strong e-commerce performance? - Improvements in Shopify performance and increased awareness of NAD contributed to e-commerce growth [54] Question: What is the company's strategy regarding supply chain risks? - The company has resolved previous supply chain issues and expects to maintain a steady supply moving forward [62] Question: What are the potential market opportunities for the Parkinson's study? - A positive outcome could significantly increase demand, with a large addressable market for those diagnosed with Parkinson's disease [112] Question: Will there be a spin-off for pharmaceutical initiatives? - A spin-off is a possibility if capital is insufficient for drug approval, but it is not currently expected [118]